1887

Abstract

strains resistant to two or more of the first line antituberculosis drugs (MDR) are a serious threat to successful tuberculosis control programmes. For this retrospective study, 85 follow-up drug resistant isolates from 23 patients residing in a community with a high incidence of tuberculosis were collected and the level of in-vitro resistance to antibiotics determined quantitatively. PCR-SSCP and sequencing techniques were used to screen for gene mutations associated with resistance in 31 follow-up samples from a smaller group of eight patients. DNA fingerprint analysis was done on sequential isolates to confirm identity. Although treatment had a profound effect on changes in drug resistance patterns, the MIC for a particular agent remained constant in follow-up isolates. DNA fingerprinting and mutational analysis (14 different loci) showed that the genome of MDR strains of is relatively stable during the course of therapy. The B gene was the most frequently mutated structural gene involved in drug resistance and a novel C to T mutation upstream of open reading frame (ORF)1 of the A operon was detected. No evidence was found of the presence of sfrain W (New York) in this group of MDR strains. The results stress the importance of confirming individuality of strains for the accurate calculation of frequencies of particular mutations associated with drug resistance, particularly in a high incidence area. Approximately one-half (47.8%) of the patients had isolates resistant to concentrations just above the critical concentration for isoniazid (MICs of 0.2–5 mg/L). Therefore, these patients and their contacts who develop primary drug-resistant tuberculosis may respond to higher dosages of treatment which could have a considerable impact on the cost and the ease of management of resistant tuberculosis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-46-10-847
1997-10-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/46/10/medmicro-46-10-847.html?itemId=/content/journal/jmm/10.1099/00222615-46-10-847&mimeType=html&fmt=ahah

References

  1. Edlin B. R., Tokars J. I., Grieco M. H. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514–1521
    [Google Scholar]
  2. Small P. M., Shafer R. W., Hopewell P. C. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 32:81137–1144
    [Google Scholar]
  3. Hinshaw H. C., Feldman W. H. Streptomycin in treatment of clinical tuberculosis: preliminary report. Proc Staphy Med Mayo Clinic 1945; 20:313–318
    [Google Scholar]
  4. Medical Research Council Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2:769–782
    [Google Scholar]
  5. Yew W. W., Chau C. H. Drug-resistant tuberculosis on the 1990s. Eur Respir J 1995; 8:1184–1192
    [Google Scholar]
  6. Musser J. M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496–514
    [Google Scholar]
  7. Heifets L. B. Drug susceptibility tests and the outcome of chemotherapy. In Heifets L. B. (ed) Drug susceptibility in the chemotherapy of mycobacterial infections CRC Boca Raton: F1, Press Inc;1–11
    [Google Scholar]
  8. National Committee for Clinical Laboratory Standards Antimicrobial susceptibility testing. Document M24-P. Villanova, PA: National Committee for Clinical Laboratory Standards; 1990
    [Google Scholar]
  9. Kent P. T., Kubica G. P. Public health mycobacteriology. A guide for the level III laboratory. Atlanta, Centers for Disease Control; 198581–82
  10. Wiid I. J. F., Werely C., Beyers N., Donald P., van Helden P. D. Oligonucleotide (GTG)5 as a marker for Mycobacterium tuberculosis strain identification. J Clin Microbiol 1994; 32:1318–1321
    [Google Scholar]
  11. Warren R., Hauman J., Beyers N. Unexpectedly high strain diversity of Mycobacterium tuberculosis in a high-incidence community. S Afr Med J 1996; 86:45–49
    [Google Scholar]
  12. Pretorius G. S., van Helden P. D., Sirgel F., Eisenach K. D., Victor T. C. Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother 1995; 39:2276–2281
    [Google Scholar]
  13. Victor T., Du Toit R., Jordaan A. M., Bester A. J., van Helden P. D. No evidence for point mutations on codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res 1990; 50:4911–4914
    [Google Scholar]
  14. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli: preliminary report. Am Rev Tuberc 1954; 69:471–472
    [Google Scholar]
  15. Zhang Y., Heym B., Allen B., Young D., Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358:591–593
    [Google Scholar]
  16. van Soolingen D., de Haas P. E. W., Blumenthal R. M. Host-mediated modification of PvuII restriction in Mycobacterium tuberculosis. J Bacteriol 1996; 178:78–84
    [Google Scholar]
  17. Heym B., Alzari P. M., Honoré N., Cole S. T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15:235–245
    [Google Scholar]
  18. Cockerill F. R., Uhl J. R., Temesgen Z. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistant. J Infect Dis 1995; 171:240–245
    [Google Scholar]
  19. Ristow M., Mӧhlig M., Rifai M., Schatz H., Feldmann K., Pfeiffer A. New isoniazid/ethionamide resistant gene mutation and screening for multidrug-resistance Mycobacterium tuberculosis strains. Lancet 1995; 346:502–503
    [Google Scholar]
  20. Banerjee A., Dubnau E., Quemard A. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227–230
    [Google Scholar]
  21. Sreevatsan S., Pan X., Stockbauer K. E., Williams D. L., Kreisworth B. N., Musser J. M. Characterization of rpsL and rrs mutations in Streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographical localities. Antimicrob Agents Chemother 1996; 40:1024–1026
    [Google Scholar]
  22. Bifani P. J., Plikaytis B. B., Kapur V. Origin and interstate spread of a New York city multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275:452–457
    [Google Scholar]
  23. Godfrey-Faussett P., Stoker N. G., Scott J. A. G., Pasvol G., Kelly P., Clancy L. DNA fingerprints of Mycobacterium tuberculosis do not change during the development of rifampicin resistance. Tuber Lung Dis 1993; 74:240–243
    [Google Scholar]
  24. Fisher S. Western Cape Regional Services Council: Annual Report of the Department of Health Services, South Africa. 1990:35–51
    [Google Scholar]
  25. Morris S., Bai G. H., Suffys P., Portillo-Gomez L., Fairchok M., Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171:954–960
    [Google Scholar]
  26. Mdluli K., Sherman D. R., Hickey M. J. Biochemical and genetic data suggest that inhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 1996; 174:1085–1090
    [Google Scholar]
  27. Devadatta S., Bhatia A. L., Andrews R. H. Response of patients infected with isoniazid-resistance tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1961; 25:807–829
    [Google Scholar]
  28. Moulding T. S. Should isoniazid be used in the retreatment of tuberculosis despite acquired isoniazid resistance?. Am Rev Respir Dis 1981; 123:262–264
    [Google Scholar]
  29. Mashimo M., Suzuki T., Abe M., Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992; 90:139–143
    [Google Scholar]
  30. Parkin D. P., Vandenplas S., Botha F. J. Trimodality of Isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1996 (in press)
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-46-10-847
Loading
/content/journal/jmm/10.1099/00222615-46-10-847
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error